← Evidence map

ArticleSensors (Basel, Switzerland)2022

New Label-Free Biosensing for the Evaluation of the AX-024 Inhibitor: Case Study for the Development of New Drugs in Autoimmune Diseases.

Yolanda Ramírez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

New Label-Free Biosensing for the Evaluation of the AX-024 Inhibitor: Case Study for the Development of New Drugs in Autoimmune Diseases. | OpenQuestion